COMPLIMENTARY WEBINAR • ADVISORY BOARD and OPTUM
The evolving market for real-world evidence: Four predictions for 2022
Thursday, February 17, 2022 | 1:00 p.m. ET
About This Webinar
- Will this be the year FDA’s real-world evidence guidelines become sufficiently robust to unlock a wide range of regulatory-grade, prospective studies using RWD?
- Are valuations for emerging real-world data and analytics companies sustainable? If there’s a bubble, will it burst in 2022?
- Is this the year that real-world data fuels meaningful cross-industry collaborations that help us reduce health disparities?
- Will we see a notable increase in outcomes-based contracts for digital therapeutics and precision medicines?
Join a panel of experts from Optum Life Sciences and Advisory Board Research as they look back on 2021 and offer their predictions about expanding sources and uses of real-world data in 2022. Sheenu Kachru, CEO of Optum Life Sciences, will join Lou Brooks, SVP of Real-World Data & Analytics for Optum Life Sciences, Solomon Banjo, Managing Director of Advisory Board’s Life Sciences Research, and Pam Divack, Advisory Board’s real-world evidence research lead, as they reflect on last year’s most significant trends and then discuss what they’re tracking most closely in 2022. Together, they’ll share four bold predictions regarding future consumption and analysis of real-world data, coupled with insights about the implications for life sciences companies, payers, providers, consumers and real-world data partners. Panelists will be available for Q&A as well.